Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 3
Overall Survival as a Driver of 1L EGFRm NSCLC Treatment Selection
Panelists discuss how overall survival is an important but not the only consideration in treatment decision-making, with factors such as patient characteristics, disease burden, and quality of life also being critical.
Weighing Overall Survival in Treatment Decisions
Main Discussion Topics:
- The relative importance of overall survival as an end point in clinical decision-making
- Additional factors beyond survival data that influence treatment selection
- Considerations regarding treatment sequencing and patient crossover between therapies
Key Points for Physicians:
- Overall survival is important but not the sole determining factor in treatment decisions
- Patient factors including age, disease burden, performance status, and social situation must be considered
- Treatment sequencing (eg, when to use amivantamab—first-line or later) requires careful consideration
Notable Insights:
The panelists note that only 1% to 2% of patients in the osimertinib arm of MARIPOSA crossed over to receive amivantamab later, raising questions about optimal sequencing strategies.
Clinical Significance:
Although overall survival data are compelling, treatment decisions require balancing efficacy with patient-specific factors and considerations of toxicity profiles and quality of life.
Related Content:
